Objective:To investigate the mechanism of KLF11 in the angiogenesis, metastasis, and invasion of colorectal cancer (CRC) by regulating the Akt/MDM2/p53 signaling pathway.Methods:Human colorectal cancer cells HCT-116 and normal colorectal mucosal epithelial cells FHC were routinely cultured, and HCT-116 cells were divided into control, pc-DNA3.1-NC, pc-DNA3.1-KLF11, and pc-DNA3.1-KLF11 + SC79 groups, and the pc-DNA3.1-KLF11 overexpression vector was transfected into the corresponding groups. KLF11 expression in CRC tissues and normal colorectal tissues was analyzed using an online tool called gene expression profiling interactive analysis (GEPIA). RT-qPCR and protein immunoblotting (WB) were used to detect changes in KLF11 expression levels and related proteins.CCK-8, cell scratch assay, and Transwell assay were used to assess cell viability, migration, and invasion ability. An angiomimetic formation assay was performed to observe angiogenesis. Western blot assay was performed to detect the effect of KLF11 on the Akt/MDM2/p53 pathway, metastasis, invasion, and angiogenesis-related protein expression. The experimental data were repeated 3 times, and the single-factor analysis of variance (ANOVA) was used for multiple group comparison, and LSD or Tamhare T2 test was used for pairwise comparison. Results:GEPIA analysis showed that KLF11 was lowly expressed in colon adenocarcinoma and rectal adenocarcinoma. KLF11 overexpression significantly decreased the viability, migration, and invasion ability of HCT-116 cells and reduced the number of angiogenesis. WB results showed that KLF11 overexpression affected the expression of key proteins in the Akt/MDM2/p53 signaling pathway, including decreased p-Akt, p-MDM2, Vimentin, VEGF, and HIF1-α proteins, while increasing the expression of p53 and E-cadherin proteins. The expression levels of the relevant proteins were reversed after treatment with the Akt inhibitor SC79.Conclusion:KLF11 inhibits the proliferative activity, migration, invasion, and angiogenesis of colorectal cancer cells by regulating the Akt/MDM2/p53 signaling pathway and may be a potential target for CRC therapy.

Objective: To analyze the diagnostic value of ultrasound guided 14 gauge coreneedle biopsy (US-CNB) in breast nodules. Methods: We retrospectively analyzed the pathological results of US-CNB and surgical excision from 373 breast nodules in Peking University International Hospital from Sep 2016 to Nov 2018 to evaluate the accuracy of 14g US-CNB. Results: A total of 349 patients(373 nodules)underwent US-CNB. US-CNB reported 282 benign lesions(75.6%, 282/373), 20 high-risklesions(5.4%, 20/373), and 71 malignant lesions(19.0%, 71/373). For 282 CNB reported benign lesions, the surgical pathology confirmed 235 lesions , 46 for high-risk lesions and 1 for malignant lesion with a concordancy of 83.3%(235/282)and the underestimation rate was 16.7%(47/282). US-CNB identified 20 high-risk lesions. According to surgical results, 15 were high-risk lesions and 5 were malignant lesions with a concordancy of 75% (15/20)and the underestimation rate was 25%(5/20). When it comes to malignant lesions, the excision results showed that 70 were malignant lesions and 1was high-risk lesion with a concordancy of 98.6%(70/71)and the overestimation rate was 1.4%(1/71). The concordance of the histological type , calculated for 50 invasive carcinomas, was 92% (46/50) with a kappa value of 0.77.The concordance of the histological grade could be calculated for 38 invasive ductal carcinomas with the Elston-Elllis Method . It was 89.5% (34/38) with a kappa value of 0.57. Conclusions The pathology result of 14gUS-CNB is in good consistency with surgical excision for breast benign and malignant lesions.

Objective To observe the therapeutic effects of different doses of recombinant human tumor necrosis factor-receptor Ⅱ:IgG Fc fusion protein (rhTNFR:Fc) on rheumatoid arthritis (RA). Methods Seventy-six patients with RA were randomly divided into rhTNFR:Fc treatment group A (n=22; rhTNFR:Fc 25 mg, twice/week and methotrexate 10 mg/week), rhTNFR:Fc treatment group B (n=24; rhTNFR:Fc 12.5mg, twice/week and methotrexate 10 mg/week) and control group (n=30; methotrexate 10 mg/week). Joint function related parameters including number of swollen joints, number of tenderness, pain degree, time of morning stiffness, Health Assessment Questionnaire (HAQ) score, erythrocyte sedimentation rate, C-reactive protein and rheumatoid factor were detected before and 2, 4, 6, 8, 12, 16 and 24 weeks after treatment in all the patients. After being treated for 3 months, the changes of joint function related paramters were evaluated and compared among groups. ACR20, ACR50 and ACR70 criteria were employed to evaluate the therapeutic effects. Results There was no significant difference in joint function related parameters among three groups before treatment (P＞0.05), while those improved significantly after treatment for 3 months (P<0.05), with more favorable results in rhTNFR:Fc treatment group A and B than in control group (P<0.05). The percent of patients with ACR50 in rhTNFR:Fc treatment group A was significantly higher than that in rhTNFR:Fc treatment group B 2 and 4 weeks after treatment (P<0.05), while there was no significant difference in total effect between these two groups 8, 12, 16 and 24 weeks after treatment(P＞0.05). Conclusion Small dose of rhTNFR:Fc in combination with methotrexate may yield effective and economical results for treatment of RA.

Objective To evaluate the efficacy and safety of etanercept in treatment of ankylosing spondylitis. MethodsEighty-six patients were randomized into experiment group and control group (n=43). Patients in experiment group were treated with non-steroidal antiinflammatory drugs (NSAIDs) and etanercept (25 mg, twice/week, subcutaneous injection in the upper arm), and those in control group were managed with NSAIDs and sulfasalazine. Reexaminations were performed after treatment for 3 months, and the prevalence of low back pain, time of morning stiffness, Bath ankylosing spondylitis disease activity index(BASDAI), Bath ankylosing spondylitis functional index(BASFI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analysed, and the prevalence of adverse effects was observed. ResultsCompared with those at administration, the prevalences of low back pain significantly reduced (P<0.05 or P<0.01), the time of morning stiffness significantly decreased (P<0.05), BASDAI and BASFI significantly improved, and ESR and CRP significantly decreased 3 months after treatment in both groups (P<0.05). After treatment for three months, the clinical parameters in experiment group were more favourable than those in control group (P<0.05). There was no significant difference in the prevalence of adverse effects between two groups (P>0.05). Conclusion Etanercept has favourable short-term therapeutic effects on ankylosing spondylitis with minor adverse effects.